<DOC>
	<DOCNO>NCT00837967</DOCNO>
	<brief_summary>The primary objective study compare tolerability Symbicort® Turbuhaler® 160/4.5 μg 10 inhalation terbutaline Turbuhaler® 0.4 mg 10 inhalation 3 day top Symbicort® Turbuhaler® 160/4.5 μg 1 inhalation twice day ( bid ) adult asthma patient .</brief_summary>
	<brief_title>Study Investigate Safety Efficacy High Dose Symbicort® SMART Japanese Patients</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Budesonide , Formoterol Fumarate Drug Combination</mesh_term>
	<mesh_term>Terbutaline</mesh_term>
	<criteria>Provision inform consent prior study specific procedures A minimum 6 month document history asthma accord JGL2006/GINA2006 definition FEV1 &gt; 70 % predict normal value prebronchodilator Having know suspected allergy study therapy ( active drug additive ) Having know clinical history hypertension , relevant arrhythmias heart disease , eg , ischemic heart disease , cardiomyopathy , valvular heart disease , heart failure Having treat oral , parenteral rectal glucocorticoid within 4 week , depot parenteral glucocorticoid within 3 month Respiratory infection significantly affect asthma , judge investigator within 4 week</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Symbicort Turbuhaler</keyword>
</DOC>